Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452519 | 1.00 | CHRNB2 (0.30) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL2917170 | 0.89 | — | — | |
| SCHEMBL2911551 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL2911265 | 0.80 | — | — | |
| SCHEMBL6050339 | 0.78 | — | — | |
| SCHEMBL1144605 | 0.74 | GLB1 (0.37) | — | |
| SCHEMBL2915812 | 0.74 | — | — | |
| SCHEMBL2916324 | 0.74 | — | — | |
| SCHEMBL2916789 | 0.73 | — | — | |
| SCHEMBL2918259 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-7358253-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-7235555-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-06-26 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | CHRNB2 1280/4885CHRNA4 1306/4885CHRNA3 1186/4885 |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | CHRNB2 4572/4885CHRNA4 4695/4885CHRNA3 4724/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | CHRNB2 1280/4885CHRNA4 1306/4885CHRNA3 1186/4885 |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | MYLK2, LCK, DGKK | CHRNB2 1183/4885CHRNA4 1220/4885CHRNA3 1143/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | CHRNB2 1224/4885CHRNA4 1672/4885CHRNA3 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.